Drugs / ICG415
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07668557 | Jun 2026 → Jul 2028 expected | acute myeloid leukemia | iCell Gene Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICG415 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07668557 ↗ |
| Known as | Anti-CD33-CLL1 CAR-T cells | “Anti-CD33-CLL1 CAR-T cells (ICG415) following lymphodepleting fludarabine and cyclophosphamide” NCT07668557 ↗ |
| Modality | Cell therapy | “This single-arm, open-label phase I trial evaluates the safety and tolerability of ICG415, autologous CAR-T cells targeting CD33 and CLL1” NCT07668557 ↗ |